首页 / 院系成果 / 成果详情页

Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients 期刊论文

编号：

c3fb5b0f-146a-49b0-be30-d2a7006deab3
作者：

Yang, DaWei(杨达伟)#^[1,2]Zhang, Yong(张勇)^[1,2]Hong, QunYing(洪群英)^[1,2]Hu, Jie(胡洁)^[1,2]Li, Chun(李春)^[1,2]Pan, BaiShen(潘柏申)^[3]Wang, Qun(王群)^[4]Ding, FeiHong^[1];Ou, JiaXian^[1];Liu, FangLei(刘芳蕾)^[1]Zhang, Dan(张丹)^[1]Zhou, JieBai(周洁白)^[1]Song, YuanLin(宋元林)^[1,2]Bai, ChunXue(白春学)*^[1,2,5]
语种：

English
期刊：

CANCER ISSN：0008-543X 2015 年 121 卷 (3113 - 3121) ; SEP 1
收录：
关键词：

biomarker delayed diagnosis non-small cell lung cancer progastrin-releasing peptide (ProGRP) small cell lung cancer
摘要：

BACKGROUNDThis study applied a combined cancer biomarker panel to clinically identify small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) in a high-risk population. METHODSThe serum levels of 4 biomarkers (progastrin-releasing peptide [ProGRP], carcinoembryonic antigen [CEA], squamous cell carcinoma antigen [SCC], and cytokeratin 19 fragment [CYFRA21-1]) were determined in 153 patients with a high risk of lung cancer (12 with a new diagnosis of SCLC, 52 with NSCLC, and 89 without lung cancer). Information about diagnosis delays was collected through interviews of all participants. RESULTSSignificantly higher serum levels of ProGRP (P<.0001) were found among the SCLC patients versus the rest of the population. A receiver operating characteristic curve analysis established the cutoff values of ProGRP, CEA, SCC, and CYFRA21-1 as 300 pg/mL, 7.3 ng/mL, 3 ng/mL, and 6.5 ng/mL, respectively. The sensitivity and specificity of ProGRP in diagnosing SCLC were 75% and 100%, respectively. Among the 14 lung cancer patients with a false-negative computed tomography (CT) result, the diagnostic panel detected 8 additional cancers. CONCLUSIONSThis panel increased the diagnostic specificity for high-risk subjects (those with renal failure being excluded), and auxiliary to a CT scan, it increased the sensitivity for patients with lung cancer. These results might be applied to shorten the diagnosis delay at health care institutions in China. Cancer 2015;121:3113-21. (c) 2015 American Cancer Society.
推荐引用方式
GB/T 7714：

Yang Da-Wei,Zhang Yong,Hong Qun-Ying, et al. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients [J].CANCER,2015,121:3113-3121.
APA：

Yang Da-Wei,Zhang Yong,Hong Qun-Ying,Hu Jie,&Bai Chun-Xue.(2015).Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients .CANCER,121:3113-3121.
MLA：

Yang Da-Wei, et al. "Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients" .CANCER 121(2015):3113-3121.

浏览次数：8  下载次数：0

分享到：

浏览次数：8

下载次数：0

打印次数：0